Python acquired $75\%$ of Slither's stock for $$316$ million in cash on January $2,2015.$ The fair value of the noncontrolling interest in Slither was $$89$ million. Slither's book value at that time was $$120$ million. The assets and liabilities reported on Slither's balance sheet had balances that approximated fair value at the date of acquisition. However, Slither had previously unreported developed technology $(10$ year life, straight$-$line$),$ valued at $$40$ million.

There has been no impairment loss on the developed technology since acquisition. Goodwill was impaired $$6$ million in $2015,$ and a $$3$ million impairment loss should be recorded for $2016.$

It is now December $31,2016.$ The trial balances of Python and Slither appear below.

$\backslash$table$[[($in thousands$),\backslash$table$[[$Python$],[$Dr $($Cr$)]],\backslash$table$[[\backslash$table$[[$Slither$],[$Dr$($Cr$)]]]]],[$Current assets,$$113,500,$$$35,000],[$Plant assets, net,$1,200,000,500,000],[$Investment in Slither,$323,800,-],[$Liabilities$,(1,342,950),(387,000)],[$Capital stock,$(40,000),(20,000)],[$Retained earnings, Jan. $1,(215,000),(110,000)],[\backslash$table$[[$Accumulated other comprehensive income,$],[$Jan$.1]],(15,000),(10,000)],[$Treasury stock,$-,5,000],[$Sales revenue,$(400,000),(100,000)],[$Equity in net income of Slither,$(2,100),-],[$Equity in OCl of Slither,$(2,250),-],[$Cost of goods sold,$250,000,35,000],[$Amortization and depreciation expense,$40,000,15,000],[$Other operating expenses,$95,000,40,000],[$Other comprehensive income,$(5,000),(3,000],[$Total$,0,0]]$

Provide the consolidated financial statements as of December $31,2016.$